597 related articles for article (PubMed ID: 28159677)
21. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
[TBL] [Abstract][Full Text] [Related]
22. BRAF mutation status in gastrointestinal stromal tumors.
Hostein I; Faur N; Primois C; Boury F; Denard J; Emile JF; Bringuier PP; Scoazec JY; Coindre JM
Am J Clin Pathol; 2010 Jan; 133(1):141-8. PubMed ID: 20023270
[TBL] [Abstract][Full Text] [Related]
23. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
Miettinen M; Sobin LH; Lasota J
Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
[TBL] [Abstract][Full Text] [Related]
24. [Translational research and diagnosis in GIST].
Wardelmann E
Pathologe; 2012 Nov; 33 Suppl 2():273-7. PubMed ID: 22968735
[TBL] [Abstract][Full Text] [Related]
25. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
[TBL] [Abstract][Full Text] [Related]
26. Multiplex mutation screening by mass spectrometry in gastrointestinal stromal tumours.
Kang G; Lee J; Jang KT; Beadling C; Corless CL; Heinrich MC; Park JO; Kang WK; Park CK; Kim KM
Pathology; 2012 Aug; 44(5):460-4. PubMed ID: 22777070
[TBL] [Abstract][Full Text] [Related]
27. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated.
Penzel R; Aulmann S; Moock M; Schwarzbach M; Rieker RJ; Mechtersheimer G
J Clin Pathol; 2005 Jun; 58(6):634-9. PubMed ID: 15917417
[TBL] [Abstract][Full Text] [Related]
28. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.
Sápi Z; Füle T; Hajdu M; Matolcsy A; Moskovszky L; Márk A; Sebestyén A; Bodoky G
Diagn Mol Pathol; 2011 Mar; 20(1):22-33. PubMed ID: 21326036
[TBL] [Abstract][Full Text] [Related]
29. High expression of the RNA-binding protein RBPMS2 in gastrointestinal stromal tumors.
Hapkova I; Skarda J; Rouleau C; Thys A; Notarnicola C; Janikova M; Bernex F; Rypka M; Vanderwinden JM; Faure S; Vesely J; de Santa Barbara P
Exp Mol Pathol; 2013 Apr; 94(2):314-21. PubMed ID: 23295309
[TBL] [Abstract][Full Text] [Related]
30. Multiple gastrointestinal stromal tumors: Clinicopathologic and genetic analysis of 12 patients.
Kang DY; Park CK; Choi JS; Jin SY; Kim HJ; Joo M; Kang MS; Moon WS; Yun KJ; Yu ES; Kang H; Kim KM
Am J Surg Pathol; 2007 Feb; 31(2):224-32. PubMed ID: 17255767
[TBL] [Abstract][Full Text] [Related]
31. SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors.
Italiano A; Chen CL; Sung YS; Singer S; DeMatteo RP; LaQuaglia MP; Besmer P; Socci N; Antonescu CR
BMC Cancer; 2012 Sep; 12():408. PubMed ID: 22974104
[TBL] [Abstract][Full Text] [Related]
32. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis.
Arne G; Kristiansson E; Nerman O; Kindblom LG; Ahlman H; Nilsson B; Nilsson O
Int J Cancer; 2011 Sep; 129(5):1149-61. PubMed ID: 21064103
[TBL] [Abstract][Full Text] [Related]
33. [Status and clinical analysis of c-kit and PDGFRA mutations in the gastrointestinal stromal tumors].
Du CY; Shi YQ; Zhou Y; Fu H; Zhao GF
Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul; 11(4):371-5. PubMed ID: 18636362
[TBL] [Abstract][Full Text] [Related]
34. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.
Miettinen M; Lasota J
Arch Pathol Lab Med; 2006 Oct; 130(10):1466-78. PubMed ID: 17090188
[TBL] [Abstract][Full Text] [Related]
35. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
[TBL] [Abstract][Full Text] [Related]
36. [c-kit and PDGFRA mutations in 60 cases of gastrointestinal stromal tumors (GISTs)].
He HY; Xiang YN; Li Y; Zhong HH; Wu BQ; Zheng J
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 37(3):320-4. PubMed ID: 15968329
[TBL] [Abstract][Full Text] [Related]
37. C-KIT and PDGFRA zygosity in gastrointestinal stromal tumors: Correlation with tumor site, tumor size, exon, and CD117 immunohistochemistry.
Wallander ML; Willmore-Payne C; Layfield LJ
Appl Immunohistochem Mol Morphol; 2011 Jan; 19(1):21-7. PubMed ID: 20823768
[TBL] [Abstract][Full Text] [Related]
38. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications.
Medeiros F; Corless CL; Duensing A; Hornick JL; Oliveira AM; Heinrich MC; Fletcher JA; Fletcher CD
Am J Surg Pathol; 2004 Jul; 28(7):889-94. PubMed ID: 15223958
[TBL] [Abstract][Full Text] [Related]
39. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.
Andersson J; Bümming P; Meis-Kindblom JM; Sihto H; Nupponen N; Joensuu H; Odén A; Gustavsson B; Kindblom LG; Nilsson B
Gastroenterology; 2006 May; 130(6):1573-81. PubMed ID: 16697720
[TBL] [Abstract][Full Text] [Related]
40. [c-Kit and PDGFRA mutations and clinico-morphological features of gastrointestinal stromal tumors].
Beliakov IS; Anurova OA; Snigur PV; Tsyganova IV; Sel'chuk VIu; Mazurenko NN
Vopr Onkol; 2007; 53(6):677-81. PubMed ID: 18416137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
